Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Expression Pathology has obtained $125,000 from the State of Maryland to develop a quantitative test for HER2 protein, an important biomarker in breast cancer tissue samples.
Subscribe to our email newsletter
The funding is part of the Maryland Technology Development’s Maryland Technology Transfer Fund (TEDCO MTTF) and the Maryland Venture Fund’s Challenge Investment Program. Using proprietary tissue processing technologies, EPI is developing a quantitative assay for HER2 (human epidermal growth factor receptor 2) in breast cancer.
Casey Eitner, president and CEO of EPI, said: “New quantitative tissue protein assays for analytes such as HER2 will be of tremendous interest for cancer research, but will also have wide application in clinical trials and patient diagnostics.”